Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04167020
Other study ID # APHP180486
Secondary ID 2019-A00770-57
Status Completed
Phase
First received
Last updated
Start date February 21, 2020
Est. completion date August 28, 2023

Study information

Verified date November 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aging of the population is a major public health problem, particularly with regard to the quality of life and the maintenance of autonomy. The fracture of the upper end of the femur (EFSF) is a pathology: - Frequent, affecting the elderly: in France, 80,000 patients / year, 83% aged ≥ 75 years (DREES, 2011), - severe, on mortality and autonomy: 40% will not recover their walking capacity earlier than 6 months, 13% of patients > 85 years old walk unaided at 4 months and 11% of patients will be newly admitted to an institution in 6 months after the fracture (UPOG / PSL data). - and costly: costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million for health insurance in France. Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond / recover from acute stress related to the EFSF. Physical resilience is an emerging concept in medicine that defines the dynamic ability of a subject to resist or recover from functional decline as a result of stress or disruption. In this context, developing new approaches to assessing resilience is important, to take into account this resilience specific to each patient in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to be able to identify, in elderly patients after an EFSF intervention, the muscular signature associated with good functional recovery (= physical resilience). The goal of the investigators is to develop software that will provide this muscle signature by measuring and analyzing parameters from high-definition surface electromyography (HD-sEMG). This technology is innovative, non-invasive and portable, CE marked but not yet used in clinical routine.


Description:

The aging of the population is a major public health problem with its multifactorial impact, quality of life and the maintenance of autonomy. The upper femoral fracture (UFF) is a common pathology: in France, it concerns nearly 80.000 patients per year, 83% of whom are aged 75 (DREES, 2011). The UFF is a pathology with serious consequences, on the mortality but also on the functional level, since 40% of the patients will not recover their walking capacity previous to 6 months, only 13% of the patients over 85 years old will walk unaided to 4 months and 11% of patients will be newly admitted to an institution within 6 months of the fracture (UPOG data, 20% for patients with major neurocognitive disorders, 4% for others). In the literature, at least 25% of elderly people will not recover their previous walking ability, especially for transfers, walking and climbing stairs (Alarcon 2011, Arinzon 2010, Visser 2000). The UFF is an expensive pathology, whose costs related to acute care (excluding prostheses and osteosynthesis equipment), are estimated at € 475 million in health insurance in France. Currently, despite optimized orthogeriatric management, it is difficult to predict how the individual will respond/recover from acute UFF-related stress. Physical resilience is an emerging concept in medicine, which defines the dynamic ability of a subject to resist or recover from a functional decline due to stress or disruption. In this context, developing new approaches to assess resilience is important, to take into account each patient's specific resilience in order to develop a personalized functional rehabilitation strategy. The objective of the HIPRESM study is to identify, in older patients after a UFF intervention, the muscle signature associated with good functional recovery (= physical resilience). The objective of the investigators is to identify the parameters derived from high definition surface electromyography (HD-sEMG) by developing software that will provide this muscle signature. This technology is innovative, non-invasive and portable, and already CE marked. Main objective: to identify HD-sEMG parameters, measured during quadriceps extension of the lower limb not affected by surgery, within 7 days post surgery for UFF, associated with functional status without human assistance (SPPB) at day 30. Main Evaluation Criterion: To investigate the association between the parameters provided by HD-sEMG (32 simultaneous channels; portable device and software, Mobita®) of the rectus femoris and functional status without human assistance measured by the Short Physical Performance Battery (SPPB = walking speed over 4 meters, chair satnds, balance) at 30 days after surgery for FESF. Secondary objectives: to study the association between parameters from HD-sEMG measured during quadriceps extension of the lower limb not affected by surgery within 7 days post surgery for FESF and : 1. the walking capacity at D30 2. the autonomy at D30 3. the walking speed over 5m at D30 4. the quality of life on D30 5. the evolution of HD-sEMG muscle quality at D30 6. in-hospital mortality and at D30 7. the time required for rehospitalization 8. the average length of stay in Follow-up Care and Rehabilitation and in the orthogeriatric stream Secondary evaluation criteria: 1. Walking ability without human assistance: autonomous walking, with technical assistance, impossible, at D30 2. Autonomy measured by the ADL scale at D30 3. Walking speed over 5 meters at D30 4. Quality of life assessed by the EQ5D questionnaire at D30 5. HD-sEMG settings at D30 6. Death in hospital and at D30 7. The time required for rehospitalization 8. The average length of stay in rehabilitation and orthogeriatric care


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date August 28, 2023
Est. primary completion date July 28, 2023
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Patient = 70 years old - Managed by orthogeriatric unit after upper femoral fracture surgery - Patient informed of the study and who has not objected to his participation. Exclusion Criteria: - Patient bedridden before the femoral fracture, with limited autonomy to bed-chair transfers - Any other associated fracture - Cutaneous allergy with adhesive plaster - BMI = 30 kg / m² - Cognitive disorders preventing the correct execution of the movement

Study Design


Related Conditions & MeSH terms


Intervention

Device:
High definition surface electromyography (HD-sEMG)
HD-sEMG data will be collected by Mobita 32® (TMSi) device

Locations

Country Name City State
France APHP - Charles Foix Hospital Ivry-sur-Seine
France APHP - Pitie Salpetriere Hospital - UPOG Paris Ile De France
France APHP - Rotschild Paris Ile De France
France APHP - Saint-Antoine Hospital Paris Ile De France

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Université de Technologie de Compiegne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary HD-sEMG correlated to SPPB Identify HD-sEMG parameters and mesured them during quadriceps muscle extension on lower limb not affected by surgery in the 7th days after UFF surgery, associated to functional status without human assistance (SPPB) at Day 30. Day 30
Secondary Walking ability at Day 30 3 possible answers: autonom walk=2, with technical assistance=1, impossible=0 a higher score meaning better outcome min value=0, maximum value=2 Day 30
Secondary Patient autonomy at Day 30 Activities of Daily Living scale (ADL scale) a hiigher score meaning better outcome min value=0, maximum value=6 Day 30
Secondary 5 meters Walking speed at Day 30 Time measurement, in second, to walk 5 meters Day 30
Secondary Quality of life at Day 30: European Quality of Life-5 Dimensions questionnaire European Quality of Life-5 Dimensions (EQ5D questionnaire) a lower score meaning better outcome min value=0, maximum value=20 Day 30
Secondary HD-sEMG parameters at Day 30 High density surface electromyogram signals obtained from rectus femoris muscle:
Maximum average amplitude obtained (mV)
Average Signal to Noise Ratio (dB)
Day 30
Secondary Intra hospital Mortality Number of patient death during hospital stay Day 30
Secondary Rehospitalization delay days between end of first hospitalization and begining of rehospitalization Day 30
Secondary Length of stay in rehabilitation care and Orthogeriatric sector Mean Length of stay Day 30